# A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL

> **NCT02135133** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 27 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Idelalisib
- **DRUG:** Ofatumumab

## Key facts

- **NCT ID:** NCT02135133
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2020-10-06
- **Final completion:** 2020-10-06
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2026-03-17

## Collaborators

- Gilead Sciences
- GlaxoSmithKline

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02135133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02135133, "A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02135133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*